Company intelligence / Profile preview

Mayne Pharma

Salisbury South, South Australia, Australiamaynepharma.com ↗

Ownership: Public · MYX
Employees: ~450
Development stage: Commercial

Overview

Mayne Pharma commercializes a broad portfolio of branded and generic pharmaceuticals with a focus on oral and topical drug delivery. The company has successfully launched multiple products in women’s health and dermatology in the US and Australia. It also provides contract development and manufacturing services globally.

Therapeutic areas: CardiovascularDermatologyWomen's HealthNeurologyInfectious Diseases
Modalities: Small moleculePeptidesTopical formulations
Industry: Biotech

Drug pipeline

1 asset

SUBA itraconazole

Partnerships

Product acquisitions from TevaProduct acquisitions from AllerganProduct acquisitions from Actavis/Allergan plc.Product acquisitions from GSKCDMO relationships with global pharma clients

Financials

Market cap: $173.4M
Total revenue: $263.8M
Enterprise value: $146.6M

Beyond the preview

Go deeper on Mayne Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mayne Pharma.